The primary end point was achievement of 75% improvement in the Eczema Area and Severity Index (EASI75) at week 16. Patients were randomized 1:1 and treated with oral upadacitinib, 30 mg once daily, or subcutaneous dupilumab, 300 mg every other week. Efficacy analyses were conducted in the intent-to-treat population. The study was conducted from February 21, 2019, to December 9, 2020, at 129 centers located in 22 countries across Europe, North and South America, Oceania, and the Asia-Pacific region. Heads Up was a 24-week, head-to-head, phase 3b, multicenter, randomized, double-blinded, double-dummy, active-controlled clinical trial comparing the safety and efficacy of upadacitinib with dupilumab among 692 adults with moderate-to-severe AD who were candidates for systemic therapy. To assess the safety and efficacy of upadacitinib vs dupilumab in adults with moderate-to-severe AD. 17 Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany.Ītopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease with an unmet need for treatments that provide rapid and high levels of skin clearance and itch improvement.16 Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.15 Medical Dermatology Associates of Chicago, Chicago, Illinois.14 Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.13 Probity Medical Research, Calgary, Alberta, Canada.12 Dermatology Research Institute, Calgary, Alberta, Canada.11 Skin Health & Wellness Centre, Calgary, Alberta, Canada.10 Division of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada.9 Division of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |